Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–9 of 9 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Elinzanetant Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn More About How Much of the Study Treatment Elinzanetant (or BAY3427080) Gets Absorbed, How Safe it is and How it Affects the Body in Healthy Female and Male Participants

NCT05351892
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes, Healthy Volunteers
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms

NCT03596762
View directory record Official record
Conditions
Menopause, Hot Flashes, Night Waking
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Mesa, Arizona • San Diego, California • Aventura, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 21, 2026, 3:56 PM EDT
Not yet recruiting No phase listed Observational

An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Symptoms in United States

NCT07490431
View directory record Official record
Conditions
Vasomotor Symptoms (VMS) Associated With Menopause
Interventions
No intervention
Other
Lead sponsor
Bayer
Industry
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Whippany, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About How Elinzanetant Works and How Safe it is in Women Having Sleep Disturbances Associated With Menopause

NCT06112756
View directory record Official record
Conditions
Sleep Disturbances Associated With Menopause
Interventions
Elinzanetant, Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
22
States / cities
Little Port Walter, Alaska • Scottsdale, Arizona • Encinitas, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause (OASIS-2)

NCT05099159
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Birmingham, Alabama • Mobile, Alabama • Peoria, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Recruiting Phase 2 Interventional

Finding Links Between Hot flASHes and CardioVascular Disease

NCT07077395
View directory record Official record
Conditions
Menopause-related Hot Flashes
Interventions
elinzanetant - reference formulation, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause

NCT05042362
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
55
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

NCT05071729
View directory record Official record
Conditions
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Interventions
Elinzanetant (BAY3427080)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 21, 2026, 3:56 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 52 Weeks in Women Who Have Been Through the Menopause

NCT05030584
View directory record Official record
Conditions
Vasomotor Symptoms Associated With Menopause, Hot Flashes
Interventions
Elinzanetant (BAY3427080), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
36
States / cities
Mobile, Alabama • Mesa, Arizona • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 21, 2026, 3:56 PM EDT